Clindamycin Injection IP 2 ml

Name: Clindamycin Injection IP 2 ml
Brand: MONARK BIOCARE PRIVATE LIMITED
Price: 127.0 INR
Availability: InStock

Price 127.0 INR/ Vial

Get a Price/Quote

Clindamycin Injection IP 2 ml Specification

Life Span
24 Month

Packaging Type
1*2ml AMP

Brand Name
Clinark-300

Salt Composition
Clindamycin Injection IP 2 ml

Drug Type
Injection

Ingredients
Clindamycin Injection IP 2 mL is a sterile solution ampoule containing 300 mg clindamycin phosphate (150 mg/mL concentration) for IM/IV use. Half the strength of the 4 mL (600 mg) ampoule, it suits initial dosing, smaller patients, outpatient IM therapy, or when lower volumes are preferred for serious anaerobic infections (Bacteroides, Clostridium), skin/soft tissue infections, pneumonia, and sepsis. IM: 300 mg undiluted q6-12h (max 1200 mg/day); IV: dilute to 18 mg/mL, infuse over 10-20 min at 30 mg/min q6-12h; total daily 600-2700 mg adults; monitor C. difficile risk.

Physical Form
Liquid

Quantity
1 Unit

Storage Instructions
cool & dry place

Clindamycin Injection IP 2 ml Trade Information

Minimum Order Quantity
100 Number

Supply Ability
500 Per Month

Delivery Time
5 Days

Clindamycin Injection IP 2 ml About

Clindamycin Injection IP 2 mL is a sterile solution containing 300 mg clindamycin phosphate (150 mg/mL) in a 2 mL ampoule for IM or IV administration.
This lincosamide antibiotic inhibits bacterial protein synthesis at the 50S ribosomal subunit, treating serious anaerobic infections (Bacteroides fragilis), Gram-positive infections (staphylococci, streptococci), skin/soft tissue infections, bone/joint infections, and intra-abdominal sepsis.

Precision Dosing for Serious Infections

Clinark-300 Clindamycin Injection IP 2 mL provides a flexible dosage suited for both initial and maintenance therapy in adults. It is engineered for use in complex infections-such as those caused by Bacteroides and Clostridium-or when smaller doses benefit patient-specific considerations. Its 150 mg/mL concentration ensures reliable, targeted antimicrobial therapy.

Convenient and Safe Administration

This sterile solution is designed for IM or IV administration. IM dosing is 300 mg undiluted every 6-12 hours (maximum 1,200 mg per day). For IV, dilute to 18 mg/mL and infuse over 10-20 minutes at a maximum of 30 mg/min. Always follow recommended protocols for administration and monitor for C. difficile associated risks.

FAQ's of Clindamycin Injection IP 2 ml:

Q: How should Clindamycin Injection IP 2 mL be administered?

A: Clinark-300 should be administered either intramuscularly (IM) undiluted or intravenously (IV) after dilution. For IV use, dilute to 18 mg/mL and infuse over 10-20 minutes at 30 mg per minute, with dosing intervals every 6 to 12 hours as directed by a healthcare provider.

Q: What are the primary uses of this injection?

A: This injection is indicated for treating serious infections such as those caused by anaerobic bacteria (Bacteroides, Clostridium), skin and soft tissue infections, community-acquired pneumonia, and sepsis, especially when precise or smaller dose volumes are optimal.

Q: When is the 2 mL (300 mg) ampoule preferable over higher-dose formulations?

A: The 2 mL ampoule is ideal for initial therapy, outpatient settings, smaller patients, or circumstances requiring lower volumes-providing effective treatment with a reduced risk of local irritation or dosing errors.

Q: Where should Clinark-300 Clindamycin Injection IP 2 mL be stored?

A: Store the ampoule in a cool and dry place, away from light and moisture, to maintain its stability throughout its 24-month shelf life. Ensure it is kept out of reach of children and only used as prescribed.

Q: What benefits does this product offer in clinical practice?

A: Its moderate dose and compact packaging allow precise titration and easy adjustment for diverse infection severities and patient needs, reducing wastage and improving safety in ambulatory or hospital settings.

Q: Is any special monitoring required during treatment?

A: Yes, patients should be monitored for possible adverse reactions, including the risk of Clostridioides difficile-associated diarrhea (CDAD), especially during prolonged or high-dose therapy.

Tell us about your requirement